Morform
Yep - exciting stuff!
But the Calimmune technology acquired by CSL is totally different to the MSB technology, unfortunately.
It is based around autologous hematopoietic stem cells - the blood forming cells - not the mesenchymal cells. And it works by taking the cells, genetically engineering them, and putting them back into the patient where they engraft and replace the patient's defective blood cells (MSB's cells do not engraft).
Their patents are not around the stem cells (this technology has been used for decades) - CSL has invested to access the genetic engineering technology. So the excitement is around the GE bit, not the stem cell bit.
There is, of course, a connection - a common complication of allogeneic hematopoietic stem cell therapy is GvHD, which we know about.
Keep Calm - it aint that bad!, page-52
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.020(1.50%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.40 | $1.34 | $3.562M | 2.615M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 17969 | 2 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |